Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838309 | 0.96 | TDP1 (0.48) | TDP1HTTATMSMN1; SMN2MAPT | |
| SCHEMBL12018109 | 0.95 | SIGMAR1 (0.49) | TDP1ATMCCR2 | |
| SCHEMBL16838295 | 0.85 | HTT (0.45) | TDP1HTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL12005236 | 0.83 | ALDH1A1 (0.40) | HTTSMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL7169664 | 0.82 | LMNA (0.52) | MAPTLMNAALDH1A1 | |
| SCHEMBL16837417 | 0.81 | ALDH1A1 (0.43) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10316572 | 0.79 | ALDH1A1 (0.57) | HTTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL12018107 | 0.79 | LMNA (0.37) | HTTSMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL12018118 | 0.79 | HTT (0.38) | TDP1HTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL12004522 | 0.78 | MAPT (0.42) | TDP1HTTSMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476683-B1 | NOVEL TETRA-AZA MACROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2019-04-03 | — | — | EP | disclosed |
| US-9353120-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-9353120-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-9061078-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-9061078-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-08-30 | — | — | US | disclosed |
| EP-2476683-A2 | NOVEL TETRA-AZA MACROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Kyungpook National University Industry- Academic Cooperation Foundation (KR) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | TDP1 4510/4885HTT 3118/4885ATM 1733/4885 |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | TDP1 4510/4885HTT 3118/4885ATM 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.